LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 12 new partner programs entered clinical development in 2023, including programs by Biotheus, Cullinan Oncology, IgM Biosciences, Inc., Invivyd, NextPoint, Sensei Biotherapeutics, Takeda, and Therini Bio. This brings the total number of Adimab partner programs that have entered the clinic to 74.
The most advanced program from Adimab’s platform is Tyvyt® (sintilimab), currently marketed in China by Innovent. Two additional products were approved and another BLA was filed in 2023. Three programs are currently in pivotal trials.
“We are thrilled to have 12 new clinical programs initiated in 2023, especially given the constrained financial market that has impacted so many biotech companies over the past few years,” said Philip T. Chase, Chief Executive Officer of Adimab. “We are proud to have helped generate a wide range of clinical molecules, including multispecifics and CAR-T programs.”
“It has been incredibly rewarding to see additional marketed programs in 2023, and we eagerly anticipate several more in 2024,” said Guy Van Meter, Chief Business Officer of Adimab. “This success is energizing to our company. Because we do not have a potentially competitive internal pipeline or venture studio, our success is fully aligned with the success of our partners.”
Adimab partners have exercised more than 95 commercial licenses to advance programs toward clinical development. Partners exercising commercial options in 2023 include Anokion, BYOMass, Compugen, IgM Biosciences, Inc., and Kelonia, among others.
Technologies
Antibody discovery: Adimab discovers therapeutic antibodies in IgG and single domain (HCab) formats through our proprietary yeast-based technology. Adimab can utilize its fully human synthetic diversity as well as additional diversities from in vivo sources. Antibodies from Adimab have exquisite specificity and are utilized as monospecific and multispecific therapies as well as CAR-Ts, ADCs, and other proteins.
Engineering: Adimab has developed and refined its engineering capabilities over thousands of lead antibody optimization efforts. The process starts with one or more partner-selected lead antibodies with the goal of optimizing potency, specificity, and/or developability. These leads can come from Adimab’s discovery process or from outside sources, typically to fix undesirable properties of antibodies from in vivo and phage-based technologies. Adimab also applies its engineering expertise to cytokines, TCRs, and other modalities.
Multispecifics and T cell engagers: Adimab has extensive multispecific capabilities that enable a variety of partner selected formats. In addition to common light chain and fragment-based discovery and engineering, Adimab has the ability to generate large panels of multispecifics for lead selection. Adimab also has proprietary solutions for both Fc (HC:HC) and Fab (HC:LC) heterodimerization to allow for the generation of numerous multispecific product designs with excellent developability properties. These are commonly coupled with Adimab’s highly characterized suite of CD3 and CD28 antibodies to generate multispecific T cell engagers.
Complex targets workflows: Certain membrane-obligate proteins (e.g., GPCRs and ion channels) are poorly behaved outside their native membrane environment. For these targets, Adimab has developed proprietary in vitro and in vivo discovery workflows that allow for discovery against membrane-obligate proteins in their native state. The company has employed these workflows numerous times to generate robust panels of specific antibodies to these classically difficult targets.
About Adimab
Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice, llama, and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies licensed non-exclusively for multispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 115 pharmaceutical and biotechnology companies, generating more than 525 therapeutic programs, over 70 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda, Vertex and others. Adimab has also partnered with many early-stage venture-backed companies, including Dragonfly, NextPoint, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Oncology, Innovent, iTeos, Mersana Therapeutics, Santa Ana Bio, Scholar Rock, and others.
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.
